Win Hlaing Than

Dr. Win Hlaing Than

Chinese University of Hong Kong, Hong Kong, China
orcid
ACTING Post Doctoral Fellow (Health Sciences), The Nethersol...

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Advances in Biomarker Sciences and Technology
Verified
Journal Article
Open access
WTWin Hlaing Than
Win Hlaing Than
GCGordon Chun-Kau Chan
Gordon Chun-Kau Chan
JNJack Kit-Chung Ng
Jack Kit-Chung Ng
CSC.C. Szeto
C.C. Szeto

18 November 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
GCGordon Chun Kau Chan
Gordon Chun Kau Chan
WTWin Hlaing Than
Win Hlaing Than
BKBonnie Ching Ha Kwan
Bonnie Ching Ha Kwan
KLKa Bik Lai
Ka Bik Lai
RCRonald Cheong Kin Chan
Ronald Cheong Kin Chan
CSC.C. Szeto
C.C. Szeto
Background: The correlation between microRNA, obesity, and glycemic intolerance in patients on peritoneal dialysis (PD) is unknown. We aimed to measure the adipose and plasma miR-221 and -222 levels, and to evaluate their association with adiposity, glucose intolerance, and new onset diabetes mellitus (NODM) after the commencement of PD. Methods: We prospectively recruited incident adult PD patients. miR-221 and -222 were measured from adipose tissue and plasma obtained during PD catheter insertion. These patients were followed for 24 months, and the outcomes were changes in adiposity, insulin resistance, and NODM after PD. Results: One hundred and sixty-five patients were recruited. Patients with pre-existing DM had higher adipose miR-221 (1.1 ± 1.2 vs. 0.7 ± 0.9-fold, p = 0.02) and -222 (1.9 ± 2.0 vs. 1.2 ± 1.3-fold, p = 0.01). High adipose miR-221 and -222 levels were associated with a greater increase in waist circumference (miR-221: beta 1.82, 95% CI 0.57–3.07, p = 0.005; miR-222: beta 1.35, 95% CI 0.08–2.63, p = 0.038), Homeostatic Model Assessment for Insulin Resistance (HOMA) index (miR-221: beta 8.16, 95% CI 2.80–13.53, p = 0.003; miR-222: beta 6.59, 95% CI 1.13–12.05, p = 0.018), and insulin requirements (miR-221: beta 0.05, 95% CI 0.006–0.09, p = 0.02; miR-222: beta 0.06, 95% CI 0.02–0.11, p = 0.002) after PD. The plasma miR-222 level predicted the onset of NODM (OR 8.25, 95% CI 1.35–50.5, p = 0.02). Conclusion: miR-221 and -222 are associated with the progression of obesity, insulin resistance, and NODM after PD.

30 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
JNJack KC Ng
Jack KC Ng
GCGordon Chun Kau Chan
Gordon Chun Kau Chan
KKKevin Ka-Ho Kam
Kevin Ka-Ho Kam
Na TianNa Tian
Na Tian
WTWin Hlaing Than
Win Hlaing Than
Philip Kam-tao LiPhilip Kam-tao Li
Philip Kam-tao Li
Patients treated with peritoneal dialysis (PD) experience complex body composition changes that are not adequately reflected by traditional anthropometric parameters. While lean and adipose tissue mass can be readily assessed by bioimpedance spectroscopy (BIS), there is concern about the potential confounding effect of volume overload on these measurements. This study aimed to assess the influence of fluid status (by echocardiography) on body composition parameters measured by BIS and to describe the longitudinal changes in adipose and lean tissue mass. We conducted a prospective observational study in a tertiary hospital. Incident Chinese PD patients underwent baseline echocardiography and repeated BIS measurements at baseline and 12 months later. Among 101 PD patients, lean tissue index (LTI) or fat tissue index (FTI) was not associated with echocardiographic parameters that reflected left ventricular filling pressure (surrogate of volume status). Sixty-eight patients with repeated BIS had a significant increase in body weight and FTI, while LTI remained similar. Gains in fat mass were significantly associated with muscle wasting (beta = −0.71, p < 0.0001). Moreover, progressive fluid accumulation independently predicted decrease in FTI (beta = −0.35, p < 0.0001) but not LTI. Body composition assessments by BIS were not affected by fluid status and should be considered as part of comprehensive nutrition assessment in PD patients.

17 January 2023 in Kidney Diseases
Verified
Journal Article
Open access
PDF file
WTWin Hlaing Than
Win Hlaing Than
JNJack KC Ng
Jack KC Ng
GCGordon Chun-Kau Chan
Gordon Chun-Kau Chan
WFWinston Fung
Winston Fung
KCKai Ming Chow
Kai Ming Chow
CSC.C. Szeto
C.C. Szeto
Introduction: Obesity at the initiation of dialysis was reported to adversely affect the clinical outcome of peritoneal dialysis (PD) patients, and weight gain is common after started on PD. However, there are few studies on the prognostic implications of weight gain after PD. Methods: We reviewed the change in body weight of 954 consecutive patients during the first 2 years of PD in a single Hong Kong center. Their subsequent clinical outcomes, including patient and technique survival rates, hospitalization, and peritonitis rates, were analyzed. Results: The mean age was 60.3 ± 12.2 years; 535 patients (56.1%) were men, and 504 (52.8%) had diabetes. From 1995–1999 to 2015–2019, the percentage of body weight gain during the first 2 years of PD was 1.0 ± 7.9%, 1.6 ± 7.1%, 1.6 ± 7.2%, 3.9 ± 9.5%, and 4.0 ± 10.3% for each 5-year period, respectively (p for linearity 5%, weight loss 2–5%, weight change with ±2%, weight gain 2–5%, and weight gain >5% during the first 2 years on PD, respectively (log-rank test, p = 0.035). With multivariable Cox regression model to adjust for clinical confounders, weight loss >5% during the first 2 years of PD was associated with a worse patient survival rate subsequently (adjusted hazard ratio 4.118, 95% confidence interval 1.040–16.313, p = 0.044), while weight gain was not associated with subsequent patient survival. Weight change during the first 2 years of PD does not appear to affect subsequent technique survival, hospitalization, decline in residual renal function, or peritonitis rate. Discussion and Conclusions: Weight gain is common during the first 2 years of PD, but weight gain does not appear to have any significant impact on the subsequent outcome. In contrast, weight loss >5% was significantly associated with worse patient survival subsequently.

12 July 2023 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
WTWin Hlaing Than
Win Hlaing Than
GCGordon Chun Kau Chan
Gordon Chun Kau Chan
BKBonnie Ching-Ha Kwan
Bonnie Ching-Ha Kwan
KLKa-Bik Lai
Ka-Bik Lai
RCRonald Cheong Kin Chan
Ronald Cheong Kin Chan
CSC.C. Szeto
C.C. Szeto
Background: Vaspin is an adipokine that regulates glucose and lipid metabolism. Plasma vaspin level is increased in chronic kidney disease but decreased in hemodialysis patients. However, plasma vaspin level in peritoneal dialysis (PD) patients, as well as its prognostic role, has not been studied. Methods: We recruited 146 incident PD patients. Their baseline plasma vaspin levels, body anthropometry, the profile of insulin resistance, bioimpedance spectroscopy parameters, dialysis adequacy, and nutritional indices were measured. They were followed for up to 5 years for survival analysis. Results: The average age was 58.4 ± 11.8 years; 96 patients (65.8%) were men, and 90 (61.6%) had diabetes. The median vaspin level was 0.18 ng/dL (interquartile range [IQR] 0.11 to 0.30 ng/dL). Plasma vaspin level did not have a significant correlation with adipose tissue mass or baseline insulin level. However, plasma vaspin level had a modest correlation with the change in insulin resistance, as represented by the HOMA-IR index, in non-diabetic patients (r = -0.358, p = 0.048). Although the plasma vaspin level quartile did not have a significant association with patient survival in the entire cohort, it had a significant interaction with diabetic status (p < 0.001). In nondiabetic patients, plasma vaspin level quartile was an independent predictor of patient survival after adjusting for confounding clinical factors (adjusted hazard ratio 2.038, 95% confidence interval 1.191–3.487, p = 0.009), while the result for diabetic patients was not significant. Conclusions: Plasma vaspin level quartile had a significant association with patient survival in non-diabetic PD patients. Baseline plasma vaspin level also had a modest inverse correlation with the subsequent change in the severity of insulin resistance, but the exact biological role of vaspin deserves further studies.

1 May 2026 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
GCGordon Chun Kau Chan
Gordon Chun Kau Chan
WTWin Hlaing Than
Win Hlaing Than
BKBonnie Ching-Ha Kwan
Bonnie Ching-Ha Kwan
KLKa-Bik Lai
Ka-Bik Lai
RCRonald Cheong Kin Chan
Ronald Cheong Kin Chan
CSC.C. Szeto
C.C. Szeto
Background: There were limited data on zinc alpha-2-glycoprotein (ZAG) levels and their association with peritoneal characteristics and clinical outcomes in patients undergoing peritoneal dialysis (PD). We aimed to quantify and explore the correlation between ZAG levels in PD effluent (PDE), adipose, and serum samples from PD patients, and to evaluate their association with peritoneal characteristics and outcome.Methods: Incident adult PD patients were enrolled in this prospective cohort study. We measured ZAG levels in PDE, serum, and pre-peritoneal fat tissue samples. Peritoneal characteristics were determined by the standard peritoneal equilibrium test. Primary and secondary outcomes were the 2-year peritonitis rate and peritonitis-related clinical outcomes, respectively.Results: We analyzed 126 patients. At baseline, PDE, adipose, and circulating ZAG levels were 1.0 ± 1.2 μg/mL, 15.3 ± 140.5-fold, and 74.4 ± 21.5 μg/mL, respectively. PDE ZAG correlated with adipose ZAG (r = 0.21, p = 0.02), but not with serum ZAG (p = 0.30). PDE ZAG independently predicted small solute peritoneal transport, i.e., dialysate-to-plasma ratio of creatinine at 4 hours (p = 0.01) and mass transfer area coefficient of creatinine (p = 0.04), but not peritoneal protein clearance (p = 0.90). After 222.7 patient-years of follow-up, 40 patients (31.7%) developed 66 peritonitis episodes, and nine patients died. PDE ZAG predicted peritonitis (unstandardized B = 0.446, p < 0.001) and peritonitis-free survival (hazard ratio, 1.36; p = 0.02) after adjustment for confounders.Conclusion: PDE ZAG level significantly correlated with peritoneal transport characteristics and was associated with peritonitis and peritonitis-free survival in PD patients.